Erin Flynt
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
-
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in
- Hematology 28
- Multiple Myeloma Research and Treatments 28
-
- Protein Degradation and Inhibitors 17
- Ubiquitin and proteasome pathways 3
- Co-authors
- Anjan Thakurta (24 shared papers)Fadi Towfic (13 shared papers)María Ortiz (7 shared papers)Sarah Gooding (7 shared papers)Hervé Avet‐Loiseau (4 shared papers)Naser Ansari‐Pour (4 shared papers)Michael Amatangelo (6 shared papers)Dan Rozelle (2 shared papers)
- Journals
- Blood (15 papers)Cell Reports Medicine (2 papers)British Journal of Haematology (2 papers)Journal of Clinical Oncology (1 paper)BMC Medical Genomics (1 paper)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Erin Flynt
26 papers receiving 439 citations
Peers
Comparison fields: 5 of 35
- Hematology 301
- Oncology 137
- Molecular Biology 306
- Pathology and Forensic Medicine 48
- Genetics 28
Countries citing papers authored by Erin Flynt
This map shows the geographic impact of Erin Flynt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Flynt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Flynt more than expected).
Fields of papers citing papers by Erin Flynt
This network shows the impact of papers produced by Erin Flynt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Flynt. The network helps show where Erin Flynt may publish in the future.
Co-authors
The 25 scholars most cited alongside Erin Flynt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 110 | |
| 2 | 2019 | 76 | |
| 3 | 2020 | 43 | |
| 4 | 2017 | 39 | |
| 5 | 2021 | 34 | |
| 6 | 2022 | 25 | |
| 7 | 2022 | 25 | |
| 8 | 2020 | 24 | |
| 9 | 2022 | 13 | |
| 10 | 2024 | 9 | |
| 11 | 2021 | 8 | |
| 12 | 2024 | 8 | |
| 13 | 2018 | 8 | |
| 14 | 2023 | 5 | |
| 15 | 2019 | 4 | |
| 16 | 2022 | 3 | |
| 17 | 2023 | 2 | |
| 18 | 2019 | 2 | |
| 19 | 2018 | 2 | |
| 20 | 2021 | 2 |
About Erin Flynt
Erin Flynt is a scholar working on Hematology, Molecular Biology, Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 29 papers that have together received 449 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (28 papers), Protein Degradation and Inhibitors (17 papers), Peptidase Inhibition and Analysis (9 papers), Cancer Mechanisms and Therapy (3 papers), Ubiquitin and proteasome pathways (3 papers), Cancer Genomics and Diagnostics (3 papers), Synthesis and Biological Activity (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Hematology (301 citations), Oncology (137 citations), Molecular Biology (306 citations), Pathology and Forensic Medicine (48 citations) and Genetics (28 citations). Erin Flynt has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Anjan Thakurta, Fadi Towfic, María Ortiz, Sarah Gooding, Hervé Avet‐Loiseau, Naser Ansari‐Pour, Michael Amatangelo, Dan Rozelle, Nizar J. Bahlis and Paresh Vyas. Their work appears in journals such as Blood, Cell Reports Medicine, British Journal of Haematology, Journal of Clinical Oncology and BMC Medical Genomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.